File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Targeted therapies in T-cell malignancies

TitleTargeted therapies in T-cell malignancies
Authors
KeywordsAlemtuzumab
Anti-Viral Therapy
Denileukin Diftitox
Histone Deacetylase Inhibitors
Monoclonal Antibodies
T-Cell Lymphomas/Leukemia
Issue Date2007
PublisherSpringer-Verlag France. The Journal's web site is located at http://www.springer.com/sgw/cda/frontpage/0,11855,4-40109-70-72816661-0,00.html?changeHeader=true
Citation
Targeted Oncology, 2007, v. 2 n. 1, p. 39-47 How to Cite?
AbstractThe World Health Organization (WHO) has classified T-cell malignancies into mature T-cell and natural killer (NK)-cell neoplasms and precursor T-cell lymphoblastic lymphoma/leukemia. Mature T-cell lymphomas, alternatively known as peripheral T-cell lymphomas (PTCLs), are rare diseases with extremely heterogeneous clinicopathologic profiles. Treatment protocols for PTCL are mostly adapted from those used for B-cell lymphomas, but the prognosis is generally worse. More recently, monoclonal antibodies, including alemtuzumab (Campath-1H, anti-CD52) and denileukin diftitox (Ontak, anti-CD25), have been shown to be effective in the treatment of T-prolymphocytic leukemia (T-PLL) and cutaneous T-cell lymphoma. The unique association of human T-cell lymphotropic virus in adult T-cell lymphoma/leukemia has also led to the use of anti-viral agents in this disease with significant improvement in outcome. A number of novel monoclonal antibodies and histone deacetylase inhibitors are also being evaluated. The roles of these targeted therapies as first-line treatment or in combination with conventional chemotherapy and the roles of autologous and allogeneic hematopoietic stem cell transplantation in PTCL need further investigation. © 2006 Springer-Verlag.
Persistent Identifierhttp://hdl.handle.net/10722/163055
ISSN
2015 Impact Factor: 3.197
2015 SCImago Journal Rankings: 1.340
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLeung, AYHen_US
dc.contributor.authorLiang, Ren_US
dc.date.accessioned2012-09-05T05:27:00Z-
dc.date.available2012-09-05T05:27:00Z-
dc.date.issued2007en_US
dc.identifier.citationTargeted Oncology, 2007, v. 2 n. 1, p. 39-47en_US
dc.identifier.issn1776-2596en_US
dc.identifier.urihttp://hdl.handle.net/10722/163055-
dc.description.abstractThe World Health Organization (WHO) has classified T-cell malignancies into mature T-cell and natural killer (NK)-cell neoplasms and precursor T-cell lymphoblastic lymphoma/leukemia. Mature T-cell lymphomas, alternatively known as peripheral T-cell lymphomas (PTCLs), are rare diseases with extremely heterogeneous clinicopathologic profiles. Treatment protocols for PTCL are mostly adapted from those used for B-cell lymphomas, but the prognosis is generally worse. More recently, monoclonal antibodies, including alemtuzumab (Campath-1H, anti-CD52) and denileukin diftitox (Ontak, anti-CD25), have been shown to be effective in the treatment of T-prolymphocytic leukemia (T-PLL) and cutaneous T-cell lymphoma. The unique association of human T-cell lymphotropic virus in adult T-cell lymphoma/leukemia has also led to the use of anti-viral agents in this disease with significant improvement in outcome. A number of novel monoclonal antibodies and histone deacetylase inhibitors are also being evaluated. The roles of these targeted therapies as first-line treatment or in combination with conventional chemotherapy and the roles of autologous and allogeneic hematopoietic stem cell transplantation in PTCL need further investigation. © 2006 Springer-Verlag.en_US
dc.languageengen_US
dc.publisherSpringer-Verlag France. The Journal's web site is located at http://www.springer.com/sgw/cda/frontpage/0,11855,4-40109-70-72816661-0,00.html?changeHeader=trueen_US
dc.relation.ispartofTargeted Oncologyen_US
dc.subjectAlemtuzumaben_US
dc.subjectAnti-Viral Therapyen_US
dc.subjectDenileukin Diftitoxen_US
dc.subjectHistone Deacetylase Inhibitorsen_US
dc.subjectMonoclonal Antibodiesen_US
dc.subjectT-Cell Lymphomas/Leukemiaen_US
dc.titleTargeted therapies in T-cell malignanciesen_US
dc.typeArticleen_US
dc.identifier.emailLeung, AYH:ayhleung@hku.hken_US
dc.identifier.emailLiang, R:rliang@hku.hken_US
dc.identifier.authorityLeung, AYH=rp00265en_US
dc.identifier.authorityLiang, R=rp00345en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1007/s11523-006-0035-0en_US
dc.identifier.scopuseid_2-s2.0-33846138610en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33846138610&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume2en_US
dc.identifier.issue1en_US
dc.identifier.spage39en_US
dc.identifier.epage47en_US
dc.identifier.isiWOS:000207054000006-
dc.publisher.placeFranceen_US
dc.identifier.scopusauthoridLeung, AYH=7403012668en_US
dc.identifier.scopusauthoridLiang, R=26643224900en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats